ClinicalTrials.gg
Not yet recruitingNCT07110194Updated Aug 7, 2025

Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies

A Phase 1 interventional study of TQB2825 Injection (Subcutaneous Injection) in CD20-positive Hematological Malignancies, sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The aim of this study is to evaluate the pharmacokinetic characteristics, safety and efficacy of the TQB2825 injection (subcutaneous administration) in patients with CD20-positive hematological malignancies.

02

Conditions studied

  • CD20-positive Hematological Malignancies
03

In context

Lead sponsor

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. is the lead sponsor of 18 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects voluntarily participated in this study, signed the form, and had good compliance;
  • Age 18 years or older and less than 80 years (calculated based on the date of signing the informed consent form);
  • (ECOG) score 0 to 2 points;
  • Expected survival greater than 12 weeks;
  • Malignant hematological tumors diagnosed by histological or cytological means, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma, etc.;
  • Immunophenotype analysis shows that the tumor is CD20 positive;
  • Previously received at least one adequate treatment with a CD20 monoclonal antibody regimen (combined chemotherapy or single drug), and the most recent adequate treatment did not lead to remission or disease progression after remission, or after hematopoietic stem cell transplantation (auto-HSCT);
  • According to the 2014 Lugano criteria, there is at least one , that is, based on Computed Tomography (CT) cross-sectional images, the long diameter of lymph node lesions is greater than 15 mm or the long diameter of extranodal lesions is greater than 10 mm; Positron Emission Tomography - Computed Tomography scan (PET-CT) scan shows positive PET;
  • Laboratory tests meet the following criteria (within 14 days before screening, no blood transfusion, no use of hematopoietic stimulating factors and other drugs to correct):

    1. (HGB) ≥ 80 g/L;
    2. (NEUT) ≥ 1.0 × 109/L;
    3. count (PLT) ≥ 75 × 109/L (if accompanied by bone marrow invasion, platelet ≥ 50 × 109/L).
    4. Total (TBIL) ≤ 1.5 times the (ULN);
    5. (ALT) and aspartate aminotransferase (AST) ≤ 2.5 ULN. If accompanied by liver , then ALT and AST ≤ 5 ULN;
    6. Serum creatinine (CR) ≤ 1.5 ULN or estimated by formula ≥ 50 ml/min.
    7. (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR) ≤ 1.5 × ULN (not receiving anticoagulant treatment);
  • Pregnant women should agree to use effective measures during the study period and within 12 months after the study ends. For men, they should agree to use effective contraceptive measures during the study period and within 12 months after the study ends.

Exclusion criteria

Exclusion Criteria:

  • Within the 5 years prior to the first medication administration, the subject had or currently has other malignant tumors. The following two situations can be included in the study: other malignant tumors treated by a single surgical procedure, achieving 5 consecutive years of disease-free survival (DFS); cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumors), Tis (in situ cancer), and T1 (tumor infiltration of the basement membrane)];
  • Previous treatment-induced adverse reactions have not recovered to a , Version 5 (CTCAEv5.0) score of ≤1, except for grade 2 alopecia, non- and asymptomatic laboratory abnormalities, stable thyroid function hypofunction after hormone replacement therapy, etc., which are judged by the investigator to have no safety risks;
  • Previous anti-tumor treatment:

    1. Within 4 weeks before the first administration, received chemotherapy, immunotherapy, monoclonal antibody treatment, radiation therapy within 2 weeks, or small molecule targeted drugs, or still within the 5 half-lives of the drug (based on the earliest occurrence time), calculate the from the end of the last treatment;
    2. Treatment with Chinese patent medicines (including Compound Banmao Capsules, Kang'ai Injection, Kanglaite Capsules/Injection, Aidi Injection, Yadanzi Oil Injection/Capsules, Xiaoaiping Tablets/Injection, Huachansu Capsules, etc.) that are explicitly approved by the National Medical Products Administration (NMPA) with anti-tumor indications in the package insert within 2 weeks prior to the first dose;
    3. Previously used other antibodies targeting both CD3 and CD20 for treatment;
    4. Received Chimeric Antigen Receptor T-cell (CAR-T) treatment, or other immune cell therapy, or hematopoietic stem cell transplantation (auto-HSCT) within 3 months before the first administration;
  • Lymphoma has previously or currently involved or is suspected to involve the central nervous system or lymphoma leukemia;
  • Within 4 weeks before the first administration, received major surgical treatment, significant traumatic injury, or expected to undergo major surgery during the study treatment, or has long-standing unhealed wounds or fractures;
  • Within 4 weeks before the first administration, experienced any bleeding or bleeding event ≥ Common Terminology Criteria for Adverse Events (CTC AE) 3 grade in the subject.
  • Within 6 months before the first administration, had a thromboembolic event such as cerebral vascular accident (including ), deep vein thrombosis, and pulmonary embolism, or any history of severe thromboembolism (implantable venous infusion port or catheter-related thrombosis, or superficial venous thrombosis is not considered "serious" thromboembolism);
  • Has clinically significant uncontrolled need for repeated drainage of pleural effusion, ascites, or moderate or above pericardial effusion; Decompensated liver cirrhosis ( liver function rating of B or C) and active hepatitis (B).
  • Pulmonary diseases, including any of the following conditions:
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    TQB2825 Injection (Subcutaneous Injection)

    The medication is administered once every two weeks, and the treatment lasts for 28 consecutive days, which constitutes one treatment cycle.

    Drug: TQB2825 Injection (Subcutaneous Injection)

Interventions

  • TQB2825 is a Cluster of Differentiation 3 × Cluster of Differentiation 20 (CD3×CD20) dual antibody, which can simultaneously target the CD20 on tumor cells and the CD3 on T cells. It can induce T cell activation, proliferation and cytokine release, and effectively target and kill tumor cells.

06

What researchers measure

Primary outcomes

  1. Peak time

    Time to peak blood concentration after a single dose

    Time frame: Up to 4 month

  2. Peak concentration Cmax

    After a single dose, the highest point of the drug-time curve is called the peak concentration.

    Time frame: Up to 4 month

  3. Plasma elimination half-life t1/2

    The amount of time it takes for the concentration of the drug in the blood, or the amount of drug in the body, to drop to about half of its original level.

    Time frame: Up to 4 month

Secondary outcomes

  1. Incidence and severity of AE and Serious Adverse Event (SAE), and abnormal laboratory test indicators

    Incidence and severity of AE and SAE, and abnormal laboratory test indicators

    Time frame: Up to 24 month

  2. Overall response rate

    To assess the percentage of patients with complete (CR) or partial response (PR) in the CD20-positive hematological tumor population who received the TQB2825 subcutaneous injection.

    Time frame: Up to 24 month

  3. Complete response rate

    To evaluate the percentage of complete response (CR) achieved by the subcutaneous injection of TQB2825 in patients with CD20-positive hematological malignancies.

    Time frame: Up to 24 month

  4. Progression-free survival period

    To evaluate the progression-free survival of TQB2825 subcutaneous injection in patients with CD20-positive hematological malignancies.

    Time frame: Up to 24 month

  5. Duration of relief

    To evaluate the duration of remission of the TQB2825 subcutaneous injection in patients with CD20-positive hematological malignancies.

    Time frame: Up to 4 month

  6. Overall survival period

    Evaluate the overall survival period of TQB2825 subcutaneous injection in patients with CD20-positive hematological malignancies.

    Time frame: Up to 4 month

  7. Immunogenicity

    Evaluation of the immunogenicity data of TQB2825 subcutaneous injection in patients with CD20-positive hematological malignancies.

    Time frame: Up to 8 month

  8. Receptor occupancy rate

    Evaluate the receptor occupancy rate of TQB2825 subcutaneous injection in patients with CD20-positive hematological malignancies.

    Time frame: Up to 6 month

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Mar 2026, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 7, 2025
StartEst.
Sep 2025
Primary completionEst.
Mar 2026
CompletionEst.
Dec 2027
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07110194
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Sep 2025 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 7, 2025

Study contacts

Yuqin Song, Master
Contact
SongYQ_VIP@163.com
010-88196118

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQB2825

Start the discussion